期刊
CLINICAL CANCER RESEARCH
卷 24, 期 12, 页码 2716-2718出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-18-0381
关键词
-
类别
资金
- Miguel Servet II contract [CPII15/00004]
- Instituto de Salud Carlos III - European FEDER funds [PI16/00668]
- MINECO [SAF2014-52361-R, SAF2017 83267 C2 1R]
- European Commission
- Cancer Research Institute (CRI) CLIP Grant
- Fundacion de la Asociacion Espanola Contra el Cancer (AECC)
- Fundacion BBVA
IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNg. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. (C) 2018 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
